GAL and type 1 diabetes mellitus: ACAs against the O-linked glycans GlcNAcβ-O-Ser (#51) were associated with islet autoimmunity and T1D progression while those against Galβ,3GalNAcα-O-Ser (Gal-Tn-Antigen, #52) were associated with T1D progression (Fig. 3).